Sunshine Biopharma Inc (SBFM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sunshine Biopharma Inc (SBFM) has a cash flow conversion efficiency ratio of -0.096x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.07 Million) by net assets ($21.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sunshine Biopharma Inc (SBFM) market capitalisation for the company's overall valuation and market capitalisation.
Sunshine Biopharma Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Sunshine Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sunshine Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sunshine Biopharma Inc ranked by their cash flow conversion efficiency. Explore SBFM cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Onix Capital Tbk
JK:OCAP
|
0.003x |
|
Pacific Resources Limited
AU:PXR
|
-0.026x |
|
Ankit Metal & Power Limited
NSE:ANKITMETAL
|
-0.018x |
|
Mdundo Com As
CO:MDUNDO
|
-0.275x |
|
ESGL Holdings Limited Ordinary Shares
NASDAQ:ESGL
|
-0.038x |
|
Netcall plc
LSE:NET
|
0.012x |
|
Seeing Machines Limited
LSE:SEE
|
-0.731x |
|
Discovery Alaska Ltd
AU:DAF
|
-0.122x |
Annual Cash Flow Conversion Efficiency for Sunshine Biopharma Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Sunshine Biopharma Inc from 2007 to 2025. View SBFM live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $23.04 Million | $-5.33 Million | -0.231x | +56.60% |
| 2024-12-31 | $23.50 Million | $-12.53 Million | -0.533x | -28.87% |
| 2023-12-31 | $21.21 Million | $-8.78 Million | -0.414x | -70.51% |
| 2022-12-31 | $21.63 Million | $-5.25 Million | -0.243x | +97.19% |
| 2021-12-31 | $211.66K | $-1.83 Million | -8.642x | -1355.36% |
| 2020-12-31 | $-954.84K | $-657.30K | 0.688x | +2.10% |
| 2019-12-31 | $-735.38K | $-495.80K | 0.674x | -92.67% |
| 2018-12-31 | $-55.75K | $-512.81K | 9.198x | +870.28% |
| 2017-12-31 | $-573.36K | $-543.52K | 0.948x | -36.73% |
| 2016-12-31 | $-209.70K | $-314.18K | 1.498x | +3.10% |
| 2015-12-31 | $-597.04K | $-867.64K | 1.453x | +4.58% |
| 2014-12-31 | $-387.58K | $-538.60K | 1.390x | -98.10% |
| 2013-12-31 | $-7.71K | $-564.40K | 73.203x | +1411.63% |
| 2012-12-31 | $70.43K | $-393.05K | -5.581x | -93.36% |
| 2011-12-31 | $103.00K | $-297.30K | -2.886x | -62.59% |
| 2010-12-31 | $196.22K | $-348.32K | -1.775x | -1597.95% |
| 2009-12-31 | $97.80K | $-10.22K | -0.105x | -108.04% |
| 2008-12-31 | $-17.71K | $-23.03K | 1.301x | +658.01% |
| 2007-12-31 | $13.39K | $-3.12K | -0.233x | -- |
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also … Read more